Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo

Journal of Immunology

Volumn 156, Issue 3, 1996, Pages 1095-1100

  Fallarino, Francesca ^a   Uyttenhove, Catherine ^a   Boon, Thierry ^a   Gajewski, Thomas F ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HISTIDINE DERIVATIVE; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; RABBIT ANTISERUM; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REJECTION;

ANIMALS; ANTIBODIES, NEOPLASM; BASE SEQUENCE; CYTOKINES; FEMALE; GRAFT REJECTION; HINDLIMB; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-12; LYMPH NODES; MAST-CELL SARCOMA; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030051657     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Rowinsky, E. K., and R. C Donehower. 1991. The clinical, pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 52:35
2. Schiff, P B., J. Fant, and S. B. Horwitz. 1979. Promotion of microtubule assembly in vitro by Taxol. Nature 277:665.
3. Schiff, P B., and S B. Horwitz. 1980. Taxol stabilizes microtubules in mouse fibroblast cells Proc Natl Acad. Sci. USA 77:1561
4. Rowinsky, E. K., R. C. Donehower, and R. J Jones. 1988. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res. 48:4093.
5. National Cancer Institute Clinical Brochure. 1991. Taxol (NSC 125973) Division of Cancer Treatment, National Cancer Institute, Bethesda, MD
6. Sredni, B., R. R. Caspi, A. Klein, Y. Kalechman, Y. Danziger, M. Ben Ya'akov, T. Tamari, F Shalit, and M Albeck. 1987. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 330 173
7. Sredni, B., Y. Kalechman, M Albeck, O. Gross, D Aurbach, P Sharon, S. N Sehgal, M. Gurwith, and H. Michlin. 1990. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase-C inducer bryostatin. Immunology 70(Suppl. 4):473
8. Kalechman, Y., M. Albeck, M. Oron, D Sobelman, M. Gurwith, S N Sehgal, and B. Sredni. 1990 The radioprotective effects of the immunomodulator AS101. J. Immunol. 145:1512
9. Shani, A., T. Tichler, R. Catane, M Gurwith, L. A Rozenszajn, A Gezin, E Levi, M. Schlesinger, Y. Kalechman, H Michlin, F. Shalit, E. Engelsman, M. Farbstein, H. Farbstein, M. Albeck, and B Sredni 1990. The immunologic effects of AS101 in the treatment of cancer patients. Nat. Immun. Cell Growth Regul. 9(Suppl 3):182
10. Sredni, B , R. Catane, A Sham, A Gezin, E. Levi, M. Schlesinger, Y Kalechman, H Michlin, F Shalit, L. A. Rosenzajn, H Farbstein, and M. Albeck. 1990. Phase I study of AS101 (an organotellunum compound) in patients with advanced malignancies. In Recent Advances in Chemotherapy. E. Rubinstein and D. Adam, eds. E. Lewin-Epstein, Jerusalem, p. 1851.4
11. Kalechman, Y , U Gafter, I. Sotnik-Barkai, M Albeck, M Gurwith, G Horwith, T. Kirsch, B Maida, S N. Sehgal, and B. Sredni. 1993. Mechanism of radio-protection conferred by the immunomodulator AS101. Exp. Hematol. 21:150
12. Kalechman, Y., I Sotnik-Barkai, M Albeck, and B. Sredni. 1993 Increased DNA repair ability following irradiation after treatment with the immunomodulator AS101. Radiat. Res. 136:197.
13. Kalechman, Y., M. Albeck, M Oron, D. Sobelman, M. Gurwith, G. Horwith, T. Kirsch, B. Maida, S N. Sehgal, and B Sredni. 1991. Protective and restorative role of AS101 in combination with chemotherapy Cancer Res. 51(Suppl. 5): 1499.
14. Kalechman, Y , I. Sotnik-Barkai, M. Albeck, and B. Sredni. 1992 The effect of AS101 on the reconstitution of T cell reactivity following irradiation or cyclophosphamide treatment. Exp. Hematol 20.1302.
15. Kalechman, Y , I. Sotnik-Barkai, M. Albeck, and B. Sredni 1993 Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-0-0′)tellurate (AS101). Cancer Res. 53(Suppl. 8):1838.
16. Kalechman, Y., I. Sotnik-Barkai, M Albeck, and B. Sredni. 1993 The protective role of AS101 in combination with several cytotoxic drugs acting by different mechanisms of action Cancer Res. 53:19.
17. Sredni, B., R. R Caspi, S Lustig, A. Klein, Y. Kalechman, Y. Danziger, M. Ben Ya'akov, T. Tamari, F Shalit, and M. Albeck. 1988. The biological activity and immunotherapeutic properties of AS101, a synthetic organotellurium compound Nat. Immun. Cell Growth Regul 7:163.
18. Sredni, B., T. Tichler, A Shani, J. Shapira, I. Bruderman, R. Catane, B. Kautman, M. Albeck, and Y. Kalechman. 1995 Bone marrow sparing and prevention of alopecia by AS101 in NSCL cancer patients treated with Carboplatin and VP-16. J. Clin. Oncol. 13:2342.
19. Kedar, E., B. Ikejin, G. D. Bonnard, and R. B. Herberman. 1982. A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell mediated cytotoxic responses. Eur. J Cancer Clin. Oncol. 18:991
20. Schabel, F. M , Jr, D P. Griswold, Jr., T. H. Corbett, W. R. Laster, Jr., J. G. Mayo, and H. H. Llyod. 1979. Testing on the therapeutic activity against advanced solid tumors of man In Cancer Drug Development, Part B, Vol 17. H. Busch and V DeVita, Jr., eds. Academic Press, Inc , New York, p 3.
21. Bissery, M. C , D. Guenard, F. Gueritte-Voegelein, and F Lavelle 1991. Experimental antitumor activity of taxotere, a Taxol analogue. Cancer Res. 51:4845.
22. Nicoletti, I., G Migliorati, M C. Pagliacci, S. Gringnam, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol. Methods 139:271
23. White, E., T. Grodzicker, and B. W. Stillman. 1984. Mutations in the gene encoding the adenovirus early region IB 19,000-molecular weight antigen cause the degradation of chromosomal DNA. J. Virol. 52:410.
24. Sentman, C. L , J. R. Shutter, D. Hockenbery, O. Kanagawa, and S. J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67:879.
25. Towbin, H., and J. Gordon. 1984. Immunoblotting and dot immunobinding: current status and outlook. J. Immunol. Methods 72:313.
26. Wyan, T. A., I. Eltoum, A. W. Cheever, F. A. J. Lewis, W. C. Gause, and A. Sher. 1993. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151:1430.
27. Lorsbach, R B., W. J. Murphy, C J. Lowenstein, S. H. Snyder, and S. W. Russell. 1993. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing, molecular basis for the synergy between interferon-γ and lipopolysaccharide. J Biol. Chem. 268:1908
28. Lowe, S. W , H. E Ruley, T. Jacks, and D E. Housman 1993. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74.957
29. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847.
30. Manthey, C. L , P V. Perera, C. A. Satkowski, and S. N. Vogel. 1994 Taxol provides a second signal for murine macrophage tumoricidal activity J. Immunol. 152.825.
31. Hibbs, J. B., R. Taintor, Z. Vavrin, and E Rachlin 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys. Res. Commun 157: 87.
32. Stuehr, D. J., and C. T. Nathan. 1989. Nitric oxide: a macrophage product responsible for cytostasis and respiration inhibition in tumor target cells. J. Exp Med. 169:1543.
33. Ross, W. C 1992. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3:311.
34. Riondel, J., M Jacrot, F. Picot, H. Beriel, C. Mounquand, and P. Potier. 1986. Therapeutic response to Taxol of six human tumors xenografted into nude mice. Cancer Chemother. Pharmacol. 17.137.
35. Clarke, A. R., C. A. Puride, D. J Hamson, R. G. Morris, C. C Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways Nature 362.849.
36. Kaufman, S. H. 1989. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotxic anticancer drugs: a cautionary note. Cancer Res 49:5870.
37. Lennon, S. V., S. J. Martin, and T G Cotter. 1991. Dose dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif. 24:203
38. Tang, C , M. C. Willingham, J. C. Reed, T Miyashita, S. Ray, V. Ponnathpur, Y. Huang, M. E. Mahoney, G. Bullock, and K. Bhalla. 1994. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells Leukemia 8:1960.
39. Kalechman, Y., I. Sotnik Barkai, M Albeck, G. Horwith, S. N. Sehgal, and B. Sredni. 1991. Use and mechanism of action of AS101 in protecting bone marrow CFU-GM after purging with ASTA-Z 7557. Cancer Res. 51:5614
40. Wolf, D., and V Rotter. 1985. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA 82:790.
41. Johnson, P , D. Gray, M. Mowat, and S. Benchimol. 1991. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell Biol. 11:1.
42. El-Deiry, W. S., W. Harper, P M. O'Connor, V. E. Velculescu, C E. Canman, J. Jackman, J. A Pietenpol, M Burrell, D. E. Hill, Y. Wang, K. G. Wiman, W. E. Mercer, M. B Kastan, K. W Kohn, S. J. Elledge, K W. Kinzler, and B. Vogelstein 1994. WAF/CIPI is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169.
43. Sheikh, M. S., X. S. Li, J. C. Chen, Z M. Shao, Z. V. Ordonez, and J A Fontana. 1994 Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9:3407.
44. Jiang, H., J Lin, Z Z. Su, F. R. Collart, E. Huberman, and P. B. Fisher. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates WAF1/Cip1 expression in the absence of p53. Oncogene 9:3397.
45. Umansky, S. 1982. The genetic program of cell death: hypothesis and some applications: transformation, carcinogenesis, aging. J Theor. Biol. 97:591.
46. Laderoute, K. R., W A. Ausserer, A. Merrill Knapp, T. D. Grant, and R. M. Sutherland. 1994. Epidermal growth factor modifies cell cycle control in A432 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res. 54:1407.
47. Mantovani, A., B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco. 1992. The origin and function of tumor-associated macrophages. Immunol. Today 13.265.
48. Ding, A. H., F. Porteu, E Sanchez, and C. F. Nathan 1990. Shared actions of endotoxin and Taxol on TNF receptors and TNF release. Science 248:370.